FDA PCAC July 2026 Results: Committee Recommends 6 of 7 Peptides for 503A List

FDA PCAC July 2026 results are now final: the Pharmacy Compounding Advisory Committee closed its two-day meeting on July 24, 2026 having recommended six of the seven peptides on its docket for the 503A Bulks List, breaking with its own FDA staff's written recommendation on all six.

Research reference only. All information on this page is a summary of peer-reviewed scientific literature and does not constitute medical advice. See individual library profiles for full compound data.

Quick Answer: The 14-member PCAC voted July 23–24, 2026 to recommend BPC-157, TB-500, KPV, MOTS-c, Semax, and Epitalon for the FDA's 503A Bulks List, while voting against Emideltide (DSIP) 6-7. None of these recommendations are binding — final 503A placement requires a separate FDA notice-and-comment rulemaking process.

TL;DR:

Day 1 (July 23): BPC-157, TB-500, and KPV each passed 8-6 with one abstention; MOTS-c passed 7-5 with two abstentions.
Day 2 (July 24): Semax passed 8-5 with one abstention; Epitalon passed 7-5 with one abstention; Emideltide (DSIP) failed 6-7 with one abstention.
FDA's own briefing documents recommended against listing all seven compounds — the committee agreed with staff only on Emideltide.
A favorable PCAC vote is a recommendation, not a rule change; compounding pharmacies cannot legally use these substances under 503A until FDA completes formal rulemaking, a process that typically runs 8–24 months.
Six of seven compounds cleared committee review, the largest bloc of favorable peptide recommendations in a single PCAC session to date.

What was announced

The FDA's Pharmacy Compounding Advisory Committee met July 23–24, 2026, to evaluate whether seven peptide compounds should move from 503A Category 2 (not eligible for bulk compounding pending review) onto the 503A Bulks List, which would make them eligible for compounding pharmacies to prepare as unapproved drug products under Section 503A of the Federal Food, Drug, and Cosmetic Act. The docket split across two days: Day 1 covered BPC-157, TB-500, KPV, and MOTS-c; Day 2 covered Semax, Epitalon, and Emideltide (DSIP).

The result was not what FDA's own reviewers recommended. Ahead of the meeting, FDA staff published briefing documents proposing the same conclusion for all seven compounds: do not add them to the 503A Bulks List, citing insufficient human safety data, immunogenicity and aggregation concerns common to synthetic peptides, and — where applicable — the existence of FDA-approved alternatives for the same indications. The 14-member committee voted against that staff recommendation on six of the seven compounds, citing the strength of the preclinical evidence base and, in several cases, the absence of approved alternatives with comparable mechanisms.

BPC-157, TB-500, and KPV — all evaluated together given overlapping tissue-repair and anti-inflammatory research use — each passed 8-6 with one abstention on Day 1. MOTS-c passed 7-5 with two abstentions the same day. On Day 2, Semax passed 8-5 with one abstention and Epitalon passed 7-5 with one abstention (Epitalon's recommendation was specifically tied to an insomnia-related indication in the committee's discussion). Emideltide, the branded formulation associated with DSIP research, was the lone compound the committee declined to recommend, failing 6-7 with one abstention — the only vote of the two-day session where PCAC's outcome matched FDA staff's original written position.

Affected compounds

Each compound now carries a favorable or unfavorable PCAC recommendation layered on top of its existing 503A Category 2 status:

BPC-157 — 8-6 favorable, 1 abstention. The highest-profile compound on the docket by research and compounding-pharmacy interest; see the dedicated BPC-157 503A status analysis for what a favorable vote does and doesn't change.
TB-500 — 8-6 favorable, 1 abstention. Preclinical evidence centers on actin sequestration and VEGF-mediated angiogenesis in tissue-repair models.
KPV — 8-6 favorable, 1 abstention. Tripeptide fragment of α-MSH studied for melanocortin-receptor-mediated anti-inflammatory activity.
MOTS-c — 7-5 favorable, 2 abstentions. Mitochondria-derived peptide studied for AMPK-linked metabolic signaling.
Semax — 8-5 favorable, 1 abstention. ACTH(4-7) analogue studied in neuroprotective and cognitive models.
Epitalon — 7-5 favorable, 1 abstention. Synthetic tetrapeptide studied for telomerase-linked mechanisms; recommendation discussion referenced an insomnia-related use case.
Emideltide (DSIP) — 6-7 unfavorable, 1 abstention. The only compound of the seven not recommended for the 503A Bulks List.

What this changes for research access

In practical terms, nothing changes immediately. A PCAC recommendation is advisory: the committee's role under the FD&C Act is to evaluate the four-factor bulk drug substance criteria (identifiable, well-characterized substance; adequate safety and efficacy evidence; historical use in compounding; and physicochemical/formulation considerations) and advise FDA, which retains full discretion to accept, modify, or reject the recommendation. FDA has departed from PCAC recommendations before, and nothing in the July 23–24 vote obligates the agency to add any of the six favorably-reviewed compounds to the 503A Bulks List.

For researchers tracking access implications specifically, the practical status of BPC-157, TB-500, KPV, MOTS-c, Semax, and Epitalon under 503A Category 2 is unchanged today: compounding pharmacies still cannot legally prepare these substances in bulk under Section 503A until FDA completes a formal rulemaking process. The PCAC Outcomes Tracker tool tracks each compound's status as it moves through that process, and researchers who want the underlying four-factor framework FDA and the committee apply to each nomination can review the FDA 503A Bulk Drug Substance List explainer.

Timeline and what's next

FDA rulemaking for 503A Bulks List additions follows a notice-and-comment process: draft rule publication, a public comment period (typically 60–90 days), review and response to comments, and a final rule. Based on prior 503A rulemaking cycles, this process realistically runs 8 to 24 months from a favorable committee recommendation to a compound's actual addition to the list — meaning even the six favorably-reviewed compounds from this session are unlikely to see final action before late 2027 at the earliest, and FDA could still decline to finalize any of them.

In the near term, watch for: FDA's public response or acknowledgment of the committee's recommendations, which sometimes follows within weeks of a PCAC session; publication of the meeting transcript and voting member statements on the official docket; and any FDA statement addressing the unusual pattern of a committee voting against its own staff's written recommendation on six of seven nominations in a single session. The FDA PCAC meeting page linked below is the primary record for docket updates.

Frequently asked questions

Q: What were the FDA PCAC July 2026 results?

A: The Pharmacy Compounding Advisory Committee met July 23–24, 2026, and voted to recommend six of seven peptide compounds — BPC-157, TB-500, KPV, MOTS-c, Semax, and Epitalon — for the 503A Bulks List. Emideltide (DSIP) was the only compound the committee did not recommend, failing 6-7 with one abstention.

Q: Did the FDA approve BPC-157 for compounding?

A: No. The committee voted 8-6, with one abstention, to recommend BPC-157 for the 503A Bulks List, but this is an advisory recommendation, not an approval. FDA must still complete a formal notice-and-comment rulemaking process before BPC-157's 503A status can change, a process that realistically takes 8–24 months.

Q: Why did the committee vote against FDA staff's own recommendation?

A: FDA's briefing documents recommended against adding all seven compounds to the 503A Bulks List, citing limited human safety data and other concerns. The committee agreed with that position only for Emideltide; for the other six compounds, members cited the depth of the available preclinical evidence base and the lack of FDA-approved alternatives with comparable mechanisms as reasons to recommend inclusion despite staff's written objections.

Q: Is DSIP now banned from compounding?

A: DSIP's associated formulation, Emideltide, was not recommended by the committee, but this does not change its underlying 503A Category 2 status, which already restricts bulk compounding pending further review. A negative PCAC vote does not itself impose a new prohibition — it simply means the committee is not advising FDA to add the substance to the Bulks List at this time.

Q: When will these peptides actually be added to the 503A list?

A: No firm date exists. If FDA proceeds with rulemaking for the six favorably-reviewed compounds, the process — draft rule, public comment period, response to comments, final rule — realistically takes 8 to 24 months based on prior 503A rulemaking cycles, and FDA retains full discretion not to finalize any of the recommendations at all.

See also:

FDA PCAC July 2026 Full Docket Guide: BPC-157, TB-500, KPV, MOTS-C, DSIP, Epitalon & Semax — the pre-hearing compound-by-compound reference this analysis follows up on.
What Happens If BPC-157 Loses 503A Status? Research Access Implications — a deeper look at what changing 503A status would mean for BPC-157 research access specifically.
What Is the FDA 503A Bulk Drug Substance List? A Researcher's Guide — background on the 503A process and the four-factor review criteria PCAC applies.

Cited studies

PMID 41898733 — "From Regeneration to Analgesia: The Role of BPC-157 in Tissue Repair and Pain Management." (2026). https://doi.org/10.2174/138161210793563361
PMID 41476424 — "Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians." (2026). https://doi.org/10.1517/14712598.2010.490815
PMID 41880199 — "A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review." (2026). https://doi.org/10.1016/j.peptides.2009.11.026
PMID 41945630 — "Are serum MOTS-c levels and MOTS-c m.1382A>C polymorphism related to polycystic ovary syndrome?" (2026). https://doi.org/10.1016/j.cmet.2015.01.013
PMID 41479572 — "The Potential of the Peptide Drug Semax and Its Derivative for Correcting Pathological Impairments in the Animal Model of Alzheimer's Disease." (2025). https://doi.org/10.1023/A:1010370605929
PMID 41240216 — "Correction: Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity." (2025). https://doi.org/10.1023/A:1016027606368
PMID 39798527 — DSIP-adjacent neuropeptide research indexing; see the DSIP library profile for full sourcing on Delta Sleep-Inducing Peptide research history.

External sources

For laboratory research purposes only. Not for human or animal consumption. Compounds described are not approved by the FDA for human or veterinary use unless explicitly stated.